- Conditions
- Hidradenitis Suppurativa
- Interventions
- Izokibep, Placebo to izokibep
- Drug
- Lead sponsor
- ACELYRIN Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Encino, California • Fountain Valley, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 2,629
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Pentamidine isethionate
- Drug
- Lead sponsor
- Fisons
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Infections, Bacterial
- Interventions
- Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Onychomycosis of Toenail
- Interventions
- SKX-16 (Luliconazole 10% Solution)
- Drug
- Lead sponsor
- SATO Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- HIV Infections, Histoplasmosis
- Interventions
- Itraconazole
- Drug
- Lead sponsor
- Janssen, LP
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 7
- States / cities
- Indianapolis, Indiana • Kansas City, Missouri • Memphis, Tennessee + 1 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- bryostatin 1, fludarabine phosphate
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 3
- States / cities
- New York, New York • Philadelphia, Pennsylvania • Richmond, Virginia
- Conditions
- Wound, Bacterial Infections, Diabetes Mellitus, Infected Ulcer of Skin
- Interventions
- Finger prick test for HbA1c measurement, Punch Biopsy, Vac Sponge Collection, Ankle Brachial Index
- Diagnostic Test · Procedure · Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Columbus, Ohio
- Conditions
- Ureaplasma, Bacterial Infection
- Interventions
- Azithromycin
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- Up to 30 Days
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Cleveland, Ohio
- Conditions
- Infections, Gram-positive Bacterial
- Interventions
- Telavancin, vancomycin or antistaphylococcal penicillin
- Drug
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- National City, California
- Conditions
- Candidiasis, Esophageal, HIV Infections
- Interventions
- L-743,872
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Rahway, New Jersey
- Conditions
- Pneumococcal Infections
- Interventions
- Multivalent, Prevnar 13, PPSV23, Saline
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 60 Years to 64 Years
- Enrollment
- 444 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 14
- States / cities
- Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
- Conditions
- Multiple Sclerosis, Relapsing Forms
- Interventions
- MEDI-551 30 MG-IV, MEDI-551 60 MG-SC, PLACEBO-IV-SC, MEDI-551 100 MG-IV, MEDI-551 300 MG-SC, MEDI-551 600 MG-IV
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Long Beach, California • Sacramento, California + 6 more
- Conditions
- Chlamydia Infection, Gonococcal Infection, Sexually Transmitted Diseases
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- San Francisco, California
- Conditions
- Pre-Eclampsia, Diphtheria, Tetanus and Pertussis Vaccine Reaction
- Interventions
- Tdap Vaccine Administration
- Drug
- Lead sponsor
- Institute of Arthritis Research
- Other
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 1,600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Idaho Falls, Idaho
- Conditions
- Onychomycosis
- Interventions
- Itraconazole 100mg capsules, Itraconazole 200mg tablets, Placebo tablets
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 1,381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Tuscon, Arizona • Hot Springs, Arkansas + 43 more
- Conditions
- Persian Gulf Syndrome, Mycoplasma Infections
- Interventions
- Doxycycline (200mg/day) or Placebo
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2001
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 23 more
- Conditions
- Onychomycosis
- Interventions
- MOB015B, Vehicle (Placebo Comparator)
- Drug
- Lead sponsor
- Moberg Pharma AB
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Encinitas, California • Fremont, California + 30 more
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- Azacitidine Injection
- Drug
- Lead sponsor
- Andrew Dinardo
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Vulvovaginal Candidiasis
- Interventions
- Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • San Diego, California • Lake Worth, Florida + 19 more
- Conditions
- Mastitis, Staphylococcus Aureus, Staphylococcal Infections
- Interventions
- Not listed
- Lead sponsor
- State University of New York - Upstate Medical University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 557 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, double-unit umbilical cord blood transplantation, total-body irradiation, tacrolimus, peripheral blood stem cell transplantation
- Drug · Procedure · Radiation
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Clostridium Difficile Infection (CDI)
- Interventions
- Fidaxomicin
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Infection, Bacterial Infection, Sepsis
- Interventions
- Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor
- Device
- Lead sponsor
- Brahms AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Camden, New Jersey • Providence, Rhode Island
- Conditions
- Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection
- Interventions
- Dalbavancin, Usual Care
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York